title: Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human             prostate cancer cell viability.
abstract: Inhibitors of CK2 kinase inhibit cell proliferation and induce apoptosis             in numerous cancer cell lines. Due to these properties, they are considered potentially             useful in anticancer therapy. In this study, we show that the exact effect of             the specific CK2 inhibitor TBB on PC-3 human prostate cancer cell viability depends             on the time schedule of administration: it was not observed when the treatment             was directly followed by the viability assay but it appeared when the treatment             and the assay were separated by a 24-h incubation without the inhibitor. Such             a pattern was maintained when the TBB treatment was combined with either camptothecin             or TRAIL. The time schedule-dependence of cell viability was not reflected by             a similar dependence of induction of apoptosis. Despite this, the schedule in             which a treatment with the CK2 inhibitor precedes that with an anticancer drug             seems to be a good choice for a potential therapy against androgen-refractory             prostate cancer.
authors: Institute of Biochemistry, Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland.
authors: Emilia
authors: E
authors: Orzechowska
authors: Ewa
authors: E
authors: Kozłowska
authors: Krzysztof
authors: K
authors: Staroń
authors: Joanna
authors: J
authors: Trzcińska-Danielewicz
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D002166:Camptothecin / Q000008:administration & dosage; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D064447:Checkpoint Kinase 2; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: C405354:4,5,6,7-tetrabromobenzotriazole; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D053221:TNF-Related Apoptosis-Inducing Ligand; D014230:Triazoles; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases; D002166:Camptothecin